Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany

[1] Elimova E(2014)Medical management of gastric cancer: a 2014 update World J Gastroenterol 20 13637-47

[2] Shiozaki H(2014)Management of gastric cancer Curr Opin Gastroenterol 30 596-602

[3] Wadhwa R(1997)Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 261-7

[4] Sudo K(2008)Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36-46

[5] Chen Q(2008)Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the arbeitsgemeinschaft internistische onkologie Ann Oncol 19 1882-7

[6] Estrella JS(2009)Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Ann Oncol 20 666-73

[7] Ku GY(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-97

[8] Ilson DH(2000)Using conjoint analysis to elicit preferences for health care BMJ 320 1530-3

[9] Webb A(2007)Patient preference methods – a patient centered evaluation paradigm ISPOR Connections 13 4-7

[10] Cunningham D(2011)Conjoint analysis applications in health--a checklist: a report of the ISPOR good research practices for conjoint analysis task force Value Health 14 403-13

[1] Elimova E(2014)Medical management of gastric cancer: a 2014 update World J Gastroenterol 20 13637-47

[2] Shiozaki H(2014)Management of gastric cancer Curr Opin Gastroenterol 30 596-602

[3] Wadhwa R(1997)Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 261-7

[4] Sudo K(2008)Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36-46

[5] Chen Q(2008)Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the arbeitsgemeinschaft internistische onkologie Ann Oncol 19 1882-7

[6] Estrella JS(2009)Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Ann Oncol 20 666-73

[7] Ku GY(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-97

[8] Ilson DH(2000)Using conjoint analysis to elicit preferences for health care BMJ 320 1530-3

[9] Webb A(2007)Patient preference methods – a patient centered evaluation paradigm ISPOR Connections 13 4-7

[10] Cunningham D(2011)Conjoint analysis applications in health--a checklist: a report of the ISPOR good research practices for conjoint analysis task force Value Health 14 403-13